Pharmacogenetics of human androgens and prostatic diseases

G. Novelli, K. Margiotti, F. Sangiuolo, J. K V Reichardt

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Prostate cancer (PCa) and benign prostatic hypertrophy (BPH) are two common and growing public health problems in the Western world. We review here the recent biochemical and pharmacogenetic literature related to these two prostatic disorders. We focus first on constitutional ('germline') single nucleotide polymorphism (SNPs) at the steroid 5α-reductase (SRD5A2) locus, which encodes the human prostatic (or Type II) steroid 5α-reductase enzyme. The investigations reviewed point to several uses of personalised medicine at the SRD5A2 locus. In addition, we report on recent identification of somatic pharmacogenetic alterations at the androgen receptor (AR) locus, which encodes the human androgen receptor, suggesting that this also may be a fruitful field of investigation, with important clinical applications. Pharmacogenomic investigation of constitutional and somatic DNA changes in human genes predisposing to cancer may lead to significant advances in chemoprevention, presymptomatic diagnosis and improved treatment of PCa.

Original languageEnglish
Pages (from-to)65-72
Number of pages8
JournalPharmacogenomics
Volume2
Issue number1
DOIs
Publication statusPublished - 2001

Fingerprint

Prostatic Diseases
Pharmacogenetics
Androgens
Prostatic Neoplasms
Oxidoreductases
Steroids
Precision Medicine
Western World
Chemoprevention
Androgen Receptors
Prostatic Hyperplasia
Single Nucleotide Polymorphism
Public Health
DNA
Enzymes
Genes
Neoplasms
Therapeutics

Keywords

  • Androgen receptor
  • Benign prostatic hypertrophy
  • Chemoprevention
  • Finasteride
  • Personalised medicine
  • Pharmacogenetics
  • Prostate cancer
  • Single nucleotide polymorphism (SNP)
  • Steroid 5α-reductase (SRD5A2)
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Cite this

Novelli, G., Margiotti, K., Sangiuolo, F., & Reichardt, J. K. V. (2001). Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics, 2(1), 65-72. https://doi.org/10.1517/14622416.2.1.65

Pharmacogenetics of human androgens and prostatic diseases. / Novelli, G.; Margiotti, K.; Sangiuolo, F.; Reichardt, J. K V.

In: Pharmacogenomics, Vol. 2, No. 1, 2001, p. 65-72.

Research output: Contribution to journalArticle

Novelli, G, Margiotti, K, Sangiuolo, F & Reichardt, JKV 2001, 'Pharmacogenetics of human androgens and prostatic diseases', Pharmacogenomics, vol. 2, no. 1, pp. 65-72. https://doi.org/10.1517/14622416.2.1.65
Novelli, G. ; Margiotti, K. ; Sangiuolo, F. ; Reichardt, J. K V. / Pharmacogenetics of human androgens and prostatic diseases. In: Pharmacogenomics. 2001 ; Vol. 2, No. 1. pp. 65-72.
@article{c150fa342e184f8ca56a960b2b5104eb,
title = "Pharmacogenetics of human androgens and prostatic diseases",
abstract = "Prostate cancer (PCa) and benign prostatic hypertrophy (BPH) are two common and growing public health problems in the Western world. We review here the recent biochemical and pharmacogenetic literature related to these two prostatic disorders. We focus first on constitutional ('germline') single nucleotide polymorphism (SNPs) at the steroid 5α-reductase (SRD5A2) locus, which encodes the human prostatic (or Type II) steroid 5α-reductase enzyme. The investigations reviewed point to several uses of personalised medicine at the SRD5A2 locus. In addition, we report on recent identification of somatic pharmacogenetic alterations at the androgen receptor (AR) locus, which encodes the human androgen receptor, suggesting that this also may be a fruitful field of investigation, with important clinical applications. Pharmacogenomic investigation of constitutional and somatic DNA changes in human genes predisposing to cancer may lead to significant advances in chemoprevention, presymptomatic diagnosis and improved treatment of PCa.",
keywords = "Androgen receptor, Benign prostatic hypertrophy, Chemoprevention, Finasteride, Personalised medicine, Pharmacogenetics, Prostate cancer, Single nucleotide polymorphism (SNP), Steroid 5α-reductase (SRD5A2), Treatment",
author = "G. Novelli and K. Margiotti and F. Sangiuolo and Reichardt, {J. K V}",
year = "2001",
doi = "10.1517/14622416.2.1.65",
language = "English",
volume = "2",
pages = "65--72",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Pharmacogenetics of human androgens and prostatic diseases

AU - Novelli, G.

AU - Margiotti, K.

AU - Sangiuolo, F.

AU - Reichardt, J. K V

PY - 2001

Y1 - 2001

N2 - Prostate cancer (PCa) and benign prostatic hypertrophy (BPH) are two common and growing public health problems in the Western world. We review here the recent biochemical and pharmacogenetic literature related to these two prostatic disorders. We focus first on constitutional ('germline') single nucleotide polymorphism (SNPs) at the steroid 5α-reductase (SRD5A2) locus, which encodes the human prostatic (or Type II) steroid 5α-reductase enzyme. The investigations reviewed point to several uses of personalised medicine at the SRD5A2 locus. In addition, we report on recent identification of somatic pharmacogenetic alterations at the androgen receptor (AR) locus, which encodes the human androgen receptor, suggesting that this also may be a fruitful field of investigation, with important clinical applications. Pharmacogenomic investigation of constitutional and somatic DNA changes in human genes predisposing to cancer may lead to significant advances in chemoprevention, presymptomatic diagnosis and improved treatment of PCa.

AB - Prostate cancer (PCa) and benign prostatic hypertrophy (BPH) are two common and growing public health problems in the Western world. We review here the recent biochemical and pharmacogenetic literature related to these two prostatic disorders. We focus first on constitutional ('germline') single nucleotide polymorphism (SNPs) at the steroid 5α-reductase (SRD5A2) locus, which encodes the human prostatic (or Type II) steroid 5α-reductase enzyme. The investigations reviewed point to several uses of personalised medicine at the SRD5A2 locus. In addition, we report on recent identification of somatic pharmacogenetic alterations at the androgen receptor (AR) locus, which encodes the human androgen receptor, suggesting that this also may be a fruitful field of investigation, with important clinical applications. Pharmacogenomic investigation of constitutional and somatic DNA changes in human genes predisposing to cancer may lead to significant advances in chemoprevention, presymptomatic diagnosis and improved treatment of PCa.

KW - Androgen receptor

KW - Benign prostatic hypertrophy

KW - Chemoprevention

KW - Finasteride

KW - Personalised medicine

KW - Pharmacogenetics

KW - Prostate cancer

KW - Single nucleotide polymorphism (SNP)

KW - Steroid 5α-reductase (SRD5A2)

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0034940666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034940666&partnerID=8YFLogxK

U2 - 10.1517/14622416.2.1.65

DO - 10.1517/14622416.2.1.65

M3 - Article

VL - 2

SP - 65

EP - 72

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 1

ER -